Profund Advisors LLC Acquires 31,478 Shares of Denali Therapeutics Inc. $DNLI

Profund Advisors LLC increased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 78.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 71,634 shares of the company’s stock after acquiring an additional 31,478 shares during the period. Profund Advisors LLC’s holdings in Denali Therapeutics were worth $1,183,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Denali Therapeutics by 8.9% in the 4th quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock worth $215,586,000 after purchasing an additional 1,064,972 shares during the period. Baillie Gifford & Co. raised its position in shares of Denali Therapeutics by 6.2% during the fourth quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock valued at $203,253,000 after buying an additional 719,304 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Denali Therapeutics by 12.2% in the third quarter. Alliancebernstein L.P. now owns 3,520,414 shares of the company’s stock worth $51,116,000 after buying an additional 383,274 shares in the last quarter. Holocene Advisors LP lifted its holdings in shares of Denali Therapeutics by 677.8% in the third quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock worth $45,531,000 after buying an additional 2,732,540 shares in the last quarter. Finally, UBS Group AG boosted its position in shares of Denali Therapeutics by 19.5% during the fourth quarter. UBS Group AG now owns 2,404,704 shares of the company’s stock worth $39,702,000 after acquiring an additional 392,351 shares during the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DNLI. Wolfe Research assumed coverage on shares of Denali Therapeutics in a research note on Monday, February 23rd. They set a “peer perform” rating for the company. Morgan Stanley decreased their price target on shares of Denali Therapeutics from $42.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, May 14th. Jefferies Financial Group restated a “buy” rating and set a $40.00 price objective on shares of Denali Therapeutics in a research report on Monday, March 2nd. Leerink Partners dropped their price target on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, April 22nd. Finally, Stifel Nicolaus raised their price target on Denali Therapeutics from $34.00 to $41.00 and gave the company a “buy” rating in a report on Thursday, March 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $35.00.

Denali Therapeutics Price Performance

DNLI stock opened at $18.83 on Thursday. Denali Therapeutics Inc. has a 52 week low of $12.58 and a 52 week high of $23.77. The firm has a market capitalization of $2.99 billion, a P/E ratio of -6.54 and a beta of 0.99. The company has a fifty day simple moving average of $19.88 and a two-hundred day simple moving average of $19.03. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.04. During the same quarter in the previous year, the firm earned ($0.78) EPS. Analysts anticipate that Denali Therapeutics Inc. will post -2.74 earnings per share for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.